Cantor Fitzgerald Downgrades Ironwood Pharmaceuticals (IRWD) to Sell

February 29, 2012 7:55 AM EST
Get Alerts IRWD Hot Sheet
Price: $4.31 +5.64%

Rating Summary:
    11 Buy, 14 Hold, 2 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Cantor Fitzgerald's Irina Rivkind downgraded shares of Ironwood Pharmaceuticals (NASDAQ: IRWD) from Hold to Sell following Q4 results Tuesday evening. Rivkind reduced her price target on the stock from $12 to $10.

The analyst cited valuation, pointing out profitability is not expected until 2017. Rivkind believes financing could be come an issue in 2013.

For an analyst ratings summary and ratings history on Ironwood Pharmaceuticals click here. For more ratings news on Ironwood Pharmaceuticals click here.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Downgrades

Related Entities

Cantor Fitzgerald, Earnings